Erectile Dysfunction news | Breaking erectile dysfunction news | Erectile Dysfunction

Second Vectura erectile drug test successful

... "It is particularly encouraging that such performance has now been demonstrated in ED patients across two separate clinical studies," Alan Riley, the principal investigator of the study, said.

Vectura said in the second double-blind placebo-controlled trial of around 600 patients, VR004 improved erectile performance, with a rapid onset of action, and was well tolerated.

"Most interestingly, the company confirmed a rapid onset of action which was previously seen in its other study ...

We remain strong buyers of Vectura," Bridgewell Analyst Elizabeth Klein said.

Vectura plans to outlicense its sexual dysfunction programme and Klein said, following these tests, she would expect it to be able to do so within the next year.

Shares in Vectura were up 1.4 percent at 88-1/2 pence in early trade, valuing the group at around 278 million pounds ($557.2 million).

Continued...

End: Story Text © Reuters 2007.

All rights reserved.

Reuters Pictures Editors Choice: Best picturesfrom the last 24 hours.View Slideshow #upsell3 { margin-right: 0px; }.upsellThumbnail { margin-right: 10px; display:inline; } .upsellThumbnail p { margin: 0px 2px 0px 2px; padding: 0px; } .upsellImage { width: 138px; height: 65px; border: 1px solid #CCC; overflow: hidden; margin-bottom: 3px; text-align: center; background: #000; } .upsellImage img { border: none; margin: 0px; } Also on Reuters #upsell1 img { margin-top: -17px; }© erectiledysfunctionnews.com, 2004
page loaded in 1.478 seconds
Resources